Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Acute Lung Injury D055371 33 associated lipids
Mucositis D052016 7 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Atherosclerosis D050197 85 associated lipids
Jaundice, Obstructive D041781 2 associated lipids
Hyperuricemia D033461 4 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Egg Hypersensitivity D021181 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Fetal Weight D020567 12 associated lipids
Stroke D020521 32 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Enterocolitis, Necrotizing D020345 3 associated lipids
Migraine without Aura D020326 1 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Venous Thrombosis D020246 11 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Brain Hemorrhage, Traumatic D020201 1 associated lipids
Thrombophilia D019851 6 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Capillary Leak Syndrome D019559 2 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Leukostasis D018921 1 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Pelvic Pain D017699 7 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Strongylida Infections D017206 5 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Liver Failure D017093 5 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Krishnamurthi S et al. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. 1984 Biochem. Pharmacol. pmid:6091666
Kamitani T et al. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. 1984 Eur. J. Pharmacol. pmid:6144557
Tokumura A et al. Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. 1984 J. Pharm. Pharmacol. pmid:6144763
Pirotzky E et al. Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. 1984 Kidney Int. pmid:6144811
Colditz IG and Movat HZ Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. 1984 J. Immunol. pmid:6088633
Knauer KA et al. Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6200443
Kazimierczak W et al. Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. 1984 Am. Rev. Respir. Dis. pmid:6201094
Malpass TW et al. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. 1984 J. Thorac. Cardiovasc. Surg. pmid:6231433
Fouque F and Vargaftig BB Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. 1984 Br. J. Pharmacol. pmid:6439269
Karlsson G and Pipkorn U Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor. 1984 Eur. J. Clin. Pharmacol. pmid:6439565
Sänze JU et al. On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. 1984 Biomed. Biochim. Acta pmid:6440544
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kulikov VI et al. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. 1984 Biokhimiia pmid:6542803
Shukla SD and Hanahan DJ Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. 1984 Arch. Biochem. Biophys. pmid:6465886
Chilton FH et al. 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. 1984 J. Biol. Chem. pmid:6434535
Doebber TW et al. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6517949
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Colditz IG and Movat HZ Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. 1984 J. Immunol. pmid:6470487
Patterson R et al. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. 1984 J. Lab. Clin. Med. pmid:6470563
Caramelo C et al. Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. 1984 Biochem. Biophys. Res. Commun. pmid:6732788
Lenihan DJ and Lee TC Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. 1984 Biochem. Biophys. Res. Commun. pmid:6732789
Kasuya Y et al. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. 1984 Can. J. Physiol. Pharmacol. pmid:6733593
Page CP et al. Platelets and bronchospasm. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6735490
Albert DH and Snyder F Release of arachidonic acid from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine, a precursor of platelet-activating factor, in rat alveolar macrophages. 1984 Biochim. Biophys. Acta pmid:6435681
Lüthje J and Ogilvie A Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP. 1984 Biochem. Biophys. Res. Commun. pmid:6704102
Clare KA and Scrutton MC The role of Ca2+ uptake in the response of human platelets to adrenaline and to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor). 1984 Eur. J. Biochem. pmid:6705791
Kumar R et al. A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. 1984 J. Lipid Res. pmid:6707528
Pelczar-Wissner CJ et al. Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. 1984 Am. J. Hematol. pmid:6720685
Guay DR and Richard A Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. 1984 Drug Intell Clin Pharm pmid:6723517
Poitevin B et al. Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. 1984 Immunopharmacology pmid:6724877
Kawaguchi H and Yasuda H Platelet-activating factor stimulates phospholipase in quiescent Swiss mouse 3T3 fibroblast. 1984 FEBS Lett. pmid:6436057
Kasuya Y et al. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). 1984 J. Pharmacobio-dyn. pmid:6726619
Schleimer RP et al. Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. 1984 J. Allergy Clin. Immunol. pmid:6208229
Nishihira J et al. Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor. 1984 Lipids pmid:6527609
Gunby P A new piece for the puzzle of inflammation. 1984 JAMA pmid:6420583
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930
Billah MM and Siegel MI Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6422930
Mojarad M et al. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. 1983 May-Jun Bull Eur Physiopathol Respir pmid:6882949
Pazzi A et al. [Platelet activation in vivo. Electron microscopy study of a case of type II diabetes]. 1983 Mar-Apr G Clin Med pmid:6884636
Satouchi K et al. Application of selected ion monitoring to determination of platelet-activating factor. 1983 J. Biochem. pmid:6423622
McManus LM et al. Thromboxane B2 (TxB2) release following acetyl glyceryl ether phosphorylcholine (AGEPC) infusion in the rabbit. 1983 Immunopharmacology pmid:6832960
Sano K et al. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. 1983 J. Biol. Chem. pmid:6218169
Mueller HW et al. 1-O-alkyl-linked phosphoglycerides of human platelets: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1983 Lipids pmid:6419001
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Tiffany ML Technical considerations for platelet aggregation and related problems. 1983 Crit Rev Clin Lab Sci pmid:6370596